Star Equity Holdings, Inc.
STRRRESTATEMENT RISKFILING INTENSITYStar Equity Holdings, Inc. reads as Restatement Risk (composite 81/100); pressure / disclosure signals dominate the posture this cycle · primary market Life Sciences.
Lens
Disclosed M&A capital (2023–2025)
$2M
vs $10M in 2020–2022
Disclosed transactions
4
3/3 active fiscal years in window
Buyer archetype
Consistent Strategic Buyer
Meaningful spend appears across repeat years.
Composite score
81
Restatement Risk dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $49M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 40d
- 294 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 28 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 2 spin pre-registrations
- Latest event 23y ago; heavily discounted
- 28 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 28 activism filings
- Latest activism 3.4y ago; discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 10-Q 207d stale
- 28 activism filings
Restatement Risk
DominantIssuers with accounting-integrity flags from filings
- 5 non-reliance 8-Ks
- 3 auditor changes
- 2 NT late filings
- Latest event 2.7y ago; discounted
Capital Velocity
Issuers with the highest filing-activity intensity
- 294 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $50M
- 10-Q 207d ago
- 4 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $6M · Peak count: 2
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 2 | $100K | $50K | N/A |
| 2024 | 1 | N/A | N/A | N/A |
| 2023 | 1 | $2M | $2M | N/A |
| 2022 | N/A | N/A | N/A | N/A |
| 2021 | 1 | $6M | $6M | N/A |
| 2020 | 1 | $4M | $4M | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Geographic Expansion20%
- Bolt On20%
- Horizontal Consolidation20%
- Talent Acquisition20%
- Tuck In20%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- geographic_expansion
- bolt_on
- horizontal_consolidation
- talent_acquisition
- tuck_in
- technology_acquisition
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“The Company’s goodwill represents the expected profit growth over time that is attributable to expanding our footprint and market share in Singapore and Southeast Asia.”
“This acquisition has enhanced Hudson RPO’s global delivery capability by adding a substantial presence in India and the Philippines”
“The Technology Group operates jointly with Hudson RPO’s existing teams in the Americas, Asia Pacific, and in Europe”
“expanded its presence in the technology sector and established a Technology Group located in San Francisco”
“Hudson Singapore is a provider of recruitment services primarily to clients operating in Singapore.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Life Sciences
- Market spend (2023–2025)
- $68.3B
- Market spend (2020–2022)
- $107.5B
- Recent vs prior
- −36%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
STRR trades at a -38.5-turn discount to the Life Sciences peer median of 16.1×.
- EV / Revenue
- 0.3×
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 16.1×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
| 19.1× | 4.7× | -0.0× | $45.2B | $10.8B | |
| 18.8× | 4.3× | -0.3× | $20.6B | $8B | |
| 13.3× | 3.5× | -0.1× | $35.5B | $2.2B | |
| 13.1× | 1.9× | -0.2× | $14.1B | $2.1B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Life Sciences. Bars scaled to the highest EV/EBITDA in the set.
Buyer landscape.
Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.
Likely buyers
No public buyers surface as a strong target-side fit on current signal.
Likely sellers / divestiture partners
No reciprocal divestiture / strategic-alternatives matches identified.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)282026-03-20
- 10-Q (quarterly)732025-11-14
- 8-K (event)2942026-03-30
- Proxy / DEF 14A622026-04-30
- Activism (13D / DFAN / PREC)282023-01-09
Signals on file
- critical
Non-reliance disclosure
2023-03-305 Item 4.02 filings on file; financial-statement non-reliance.
- elevated
Auditor change
2023-10-043 Item 4.01 filings on file; certifying accountant change.
- watch
Late-filing notice
2023-03-312 NT 10-K/10-Q filings on file.
- elevated
Spin registration
2003-03-142 Form 10-12 filings on file; pre-spin registration.
- elevated
Activism on file
2023-01-0928 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Spin/Carve candidate
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.